On Mar. 15, 2021, Adamis Pharma announced that in studies conducted at Galveston National Laboratory, University of Texas Medical Branch at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls.

This was the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19.